Laipẹ, Novo Nordisk ṣe ifilọlẹ ni ifowosi ijabọ inawo 2022 rẹ. Data fihan wipe Novo Nordisk ká lapapọ tita ni 2022 yoo de ọdọ 176.954 bilionu Danish krone (US $24.994 bilionu, awọn iyipada oṣuwọn paṣipaarọ kede ninu awọn lododun Iroyin, kanna ni isalẹ), soke 26% odun lori odun, awọn ọna èrè yoo de ọdọ 74.809 bilionu Danish krone. (US $ 10.566 bilionu), soke 28% odun lori odun, ati net èrè yoo jẹ 55.525 bilionu Danish krone (US $ 7.843 bilionu), soke 16% odun lori odun. Awọn iṣẹ jẹ gidigidi ìkan.

Nibo ni iṣẹ iyalẹnu Novo Nordisk ti wa? Idahun si jẹ afọwọṣe GLP-1. Ninu opo gigun ti ọja Novo Nordisk, awọn ọja le pin si awọn oriṣi mẹrin: awọn analogues GLP-1, hisulini ati awọn analogues, awọn ifosiwewe coagulation ati awọn homonu ti iṣelọpọ miiran, pẹlu tita 83.371 bilionu Danish krone ($ 11.176 bilionu, laisi awọn abẹrẹ pipadanu iwuwo), 52.952 bilionu Danish krone ($ 7.479 bilionu), 11.706 Danish krone ($ 1.653 bilionu) ati 7.138 bilionu Danish krone ($ 1.008 bilionu), lẹsẹsẹ. Lara awọn analogues GLP-1, awọn tita ti abẹrẹ hypoglycemic Liraglutide ti dinku ni ọdun nipasẹ ọdun, lakoko tiSemaglutidejẹ mimu oju pupọju, pẹlu apapọ awọn titaja ti 10.882 bilionu owo dola Amerika ni ọdun 2022.